IRADIMED CORPORATION

NasdaqGM:IRMD Stock Report

Market Cap: US$1.1b

IRADIMED Future Growth

Future criteria checks 1/6

IRADIMED is forecast to grow earnings and revenue by 13.4% and 10.6% per annum respectively while EPS is expected to grow by 13.3% per annum.

Key information

13.4%

Earnings growth rate

13.27%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate10.6%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Aug 2026

Recent future growth updates

Recent updates

Analysis Article • Jun 22

IRADIMED (IRMD) Stock Could Be 21.9% Undervalued on Its MRI Pump Upgrade Narrative

With no single headline event driving attention to IRADIMED (IRMD) today, investors are instead looking at the stock’s recent performance record and financial profile to reassess how it fits into a healthcare portfolio. See our latest analysis for IRADIMED. IRADIMED’s share price has been choppy in recent months, with the stock down around 7% over 90 days and 3% year to date, yet its 1 year total shareholder return of about 61% and 5 year total shareholder return above 250% still point to...
Narrative Update • Jun 18

IRMD: 2026 Guidance And Bullish Initiation Will Drive Further Re Rating

Analysts have maintained their $118 price target on IRADIMED, citing recent bullish initiation and supporting research that highlight the company's long-term earnings potential, along with a still-elevated forward P/E profile. What’s in the News for IRADIMED IRADIMED issued earnings guidance for the second quarter of 2026, with expected revenue in a range of US$20.0 million to US$21.0 million and GAAP diluted EPS between US$0.40 and US$0.44.
Narrative Update • Jun 04

IRMD: 2026 Guidance And Bullish Coverage Will Support Further Re Rating

Analysts have nudged their price target on IRADIMED slightly lower, from about $118.67 to $118.00. They are refining assumptions around discount rates, revenue growth, margins and future P/E expectations following recent bullish Street coverage.
Narrative Update • Apr 30

IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating

Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.
Narrative Update • Apr 12

IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating

Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.
Narrative Update • Mar 26

IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating

Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.
Narrative Update • Mar 11

IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing

Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.
Narrative Update • Feb 25

IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple

Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.
Narrative Update • Feb 10

IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support

Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.
Narrative Update • Jan 27

IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook

Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.
Narrative Update • Jan 12

IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced

Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.
Narrative Update • Dec 14

IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks

Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.
Narrative Update • Nov 29

IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks

IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.
Narrative Update • Nov 15

IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum

Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.
Narrative Update • Nov 01

IRMD: Index Addition and Strong Margins Will Support Measured Upside

Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.
Analysis Article • Oct 09

Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Aug 13

IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up

Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...
Analysis Article • Aug 08

IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues

NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...
Analysis Article • Jun 01

Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
User avatar
New Narrative • Sep 24

Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins

Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.
Analysis Article • Aug 08

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...
Analysis Article • Feb 23

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analysis Article • Feb 07

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...
Analysis Article • Nov 06

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...
Analysis Article • Oct 13

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...

Earnings and Revenue Growth Forecasts

NasdaqGM:IRMD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281133218301
12/31/20271012822282
12/31/2026912518232
6/30/202686232527N/A
3/31/202686242429N/A
12/31/202584221725N/A
9/30/202581211425N/A
6/30/202578211327N/A
3/31/202575201426N/A
12/31/202473191726N/A
9/30/202471191724N/A
6/30/202469191316N/A
3/31/202468181113N/A
12/31/20236617513N/A
9/30/20236316513N/A
6/30/20236015715N/A
3/31/20235614513N/A
12/31/20225313810N/A
9/30/20225013910N/A
6/30/20224812910N/A
3/31/202245101112N/A
12/31/20214291111N/A
9/30/20213861010N/A
6/30/202135588N/A
3/31/202132156N/A
12/31/202032156N/A
9/30/202034477N/A
6/30/202036589N/A
3/31/20203910N/A11N/A
12/31/20193910N/A10N/A
9/30/2019368N/A10N/A
6/30/2019348N/A7N/A
3/31/2019327N/A6N/A
12/31/2018306N/A7N/A
9/30/2018295N/A5N/A
6/30/2018273N/A6N/A
3/31/2018252N/A5N/A
12/31/2017230N/A3N/A
9/30/2017221N/A4N/A
6/30/2017243N/A6N/A
3/31/2017295N/A7N/A
12/31/2016327N/A9N/A
9/30/2016358N/A10N/A
6/30/2016359N/A9N/A
3/31/2016338N/A9N/A
12/31/2015318N/A8N/A
9/30/2015265N/A4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IRMD's forecast earnings growth (13.4% per year) is above the savings rate (3.7%).

Earnings vs Market: IRMD's earnings (13.4% per year) are forecast to grow slower than the US market (17.2% per year).

High Growth Earnings: IRMD's earnings are forecast to grow, but not significantly.

Revenue vs Market: IRMD's revenue (10.6% per year) is forecast to grow slower than the US market (13.4% per year).

High Growth Revenue: IRMD's revenue (10.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IRMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 22:46
End of Day Share Price 2026/09/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IRADIMED CORPORATION is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lawrence SolowCJS Securities, Inc.
Ilya ZubkovFreedom Broker
Frank TakkinenLake Street Capital Markets, LLC